期刊文献+

低剂量螺内酯治疗充血性心力衰竭临床疗效观察

Treatment of congestive heart failure with low-dose spironolactone
暂未订购
导出
摘要 目的观察低剂量螺内酯治疗充血性心力衰竭(CHF)的临床疗效。方法100例CHF患者随机分成螺内酯组52例,对照组48例,螺内酯组在常规治疗的基础上加用螺内酯20-40mg/d,连续应用8周以上。结果螺内酯组与对照组比较左室射血分数、每搏输出量和临床疗效差异有显著性(P〈0.05)。结论螺内酯治疗充血性心力衰竭有较好的临床疗效,可改善心功能和临床症状,降低病死率。 Objective To evaluate the clinical efficacy of low-dose spironolactone treatment on congestive heart failure (CHF) .Methods 52 patients received low-dose spironolactone 20-40 mg a day for 8 weeks, with the routine treatment. Results Compared with those in control group, EF volume, stroke volume in spironolactone treatment group were significantly increased. In Addition, the clinical manifestations were also improved in spironolactone treatment group ( P 〈 0.05). Conclusion The low-dose spironolactone is effective in treating congestive heart failure, which could improve clinical manifestation and the heart function, which also could decrease the mortality.
作者 鲍然
出处 《河北医药》 CAS 2006年第3期176-177,共2页 Hebei Medical Journal
关键词 充血性心力衰竭 螺内酯 心衰治疗 congestive heart failure spironolactone therapy for heart failure
  • 相关文献

参考文献5

二级参考文献42

  • 1COHN J N, INDER S A, ROBERTO L, et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the valsartan heart failure trial [J], Circulation, 2003,108(11) :1306-1309.
  • 2McKELVIE R S, YUSUF S, PERICAK D, et al. Comparison of eandesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study [J], The RESOLVD Pilot Study Investigators. Circulation, 1999, 100(10) : 1056-1064.
  • 3COHN J N, TOGNONI G. Valsartan heart failure trial investigators. A randomized trial of angiotensin-receptor blocker valsartan in chronic heart failure [J]. N Engl J Med,2001, 345(23):1667 1675.
  • 4HARADA E, YOSHIMURA M, YASUE H, el al.Aldosterone induces angiot ensin-conver ting enzyme gene expression in cultured Neonatal Rat Cardiocytes [ J].Circulation, 2001, 104(2) : 137-139.
  • 5PITT B, ZANNAD F, REMME W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J]. N Engl J Med, 1999, 341(6): 709-717.
  • 6KAMBARA A, HOLYCROSS B J, WUNG P, et al.Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure [J]. J Am Heart Association, 2003, 41(6):830-837.
  • 7RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]) [J]. Am J Cardiol,1996,78(8) : 902-907.
  • 8NANCY J B. Eplerenone Cardiovascular Protection [ J ].Circulation, 2003, 107(19) :2512-2518.
  • 9Mc MAHON E G, L()UIS S T. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist[J]. Current Opinion in Pharmacology, 2001, 1(2):190-196.
  • 10BERTRAM Pitt, REMME W, ZANNAD F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J].New England J Med, 2003, 348(24):2309-2322.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部